Overall survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
Summary of findings table (subcomparison 2): second‐line… may leads to lower progression‐free survival compared with control intervention alone (low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone may leads to lower sudden cardiac death compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with beta blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Sudden cardiac death · beta blockers
Amiodarone showed no clear difference in sudden cardiac death compared with beta blockers (low certainty).
1 finding from 1 review
All‐cause mortality · beta blockers
Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in sudden cardiac death compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with other antiarrhythmics (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review